Other therapy.
Cost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreOther therapy.
The Breast 76 (2024) 103752 Author: Mansani et al.
Read More: Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreSSO 2024 Author: Solis-Pomales et al.
Read MoreJournal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read More2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA) Presenter: Wolf et al.
Read MoreSABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreSABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreSABCS 2023, PO4-02-02 Authors: Sivapiragasam et al.
Read MoreSABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreSABCS 2023, PO3-02-02 Authors: JJ Alberty-Oller, et al.
Read More